Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

Market Cap	221.64B
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	23.26M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,210
Average Volume	180,964
Open	9,570
Previous Close	9,530
Day's Range	9,510 - 10,170
52-Week Range	6,970 - 13,700
Beta	2.42
RSI	55.68
Earnings Date	Nov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 323990

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.